CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤 CAR-T 细胞治疗耐药机制：2024 ASH 年会最新进展
英文原题：Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting.
查看英文原题
Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法在治疗多发性骨髓瘤（MM）方面显示出显著潜力，但 CAR-T 耐药仍是关键挑战。研究抗原逃逸、免疫抑制和 CAR-T 细胞耗竭等耐药机制，对于增强这一治疗方法的长期疗效至关重要。本文深入综述了第 66 届 ASH 年会报告的最新研究结果。
展开英文摘要原文
Chimeric Antigen Receptor T-Cell (CAR-T) therapy demonstrates significant potential in the treatment of multiple myeloma (MM).
However, resistance to CAR-T therapy remains a critical challenge. Investigating the mechanisms underlying CAR-T resistance, including antigen escape, immunosuppression, and CAR-T cell exhaustion, is essential for enhancing the long-term efficacy of this therapeutic approach.
This study provides an in-depth review of the latest findings presented at the 66th ASH Annual Meeting.
论文信息
- 作者
- Hu Y、Hou J、Jiang Z、Lin Q
- 第一作者单位
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.China
- 通讯作者单位
- The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China. zlyylinquande1577@zzu.edu.cn.China
- 文献类型
- 读者来信
- 期刊
- Experimental hematology & oncology2025 Mar 26
- 原文标识
- PubMed 40140947 · DOI 10.1186/s40164-025-00643-6
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →